On May 22, 2023 Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, reported that it has commenced an underwritten public offering of $250.0 million of its common stock (Press release, Guardant Health, MAY 22, 2023, View Source [SID1234631933]). In addition, Guardant Health intends to grant the underwriters a 30-day option to purchase up to $37.5 million of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by Guardant Health. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
J.P. Morgan, Goldman Sachs & Co. LLC, TD Cowen and SVB Securities are acting as joint book-running managers for the proposed offering.
The shares of common stock are being offered by Guardant Health pursuant to an automatic shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission, or the SEC, and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained by contacting:
J.P. Morgan Securities LLC
c/o Broadridge Financial Solutions
1155 Long Island Avenue, Edgewood, NY 11717
Telephone: (866) 803-9204, or email: [email protected];
Goldman Sachs & Co. LLC
Attention: Prospectus Department
200 West Street, New York, NY 10282
Telephone: (866) 471-2526, or email: [email protected];
Cowen and Company, LLC
599 Lexington Avenue, New York, NY 10022
Telephone: (833) 297-2926, or email: [email protected];
SVB Securities LLC
Attention: Syndicate Department
53 State Street, 40th Floor, Boston, MA 02109
Telephone: (800) 808-7525, ext. 6105, or email: [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.